Aims and objectives of this presentation
PSA recurrence after curative treatments is a common problem. During this session we will discuss the patient profile in this situation and 2 adjuvant or salvage modalities with either radiation or PSMA radio guided surgery.

*430
Patterns of clinical recurrence and predictors of systemic progression of prostate cancer patients with PSA persistence after radical prostatectomy
By: Gandaglia G.¹, Fossati N.², Dell'Oglio P.¹, Damiano R.³, Bianchi M.³, Picozzi M.², Farina E.², Cucchiara V.², Bertini R.², Dehò F.², Montorsi F.¹, Briganti A.³
Institutes: IRCCS Ospedale San Raffaele; Uri, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, ³Magna Graecia University of Catanzaro, Dept. of Urology, Catanzaro, Italy

*431
External validation of a model predicting survival of men with recurrent prostate cancer after radical prostatectomy
By: Dell'Oglio P.¹, Suardi N.¹, Boorjian S.², Fossati N.¹, Gandaglia G.¹, Tian Z.³, Moschini M.¹, Capitanio U.¹, Karakiewicz P.³, Montorsi F.¹, Karnes J.², Briganti A.¹
Institutes: IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, United States of America, ³University of Montreal Health Center, Dept. of Cancer Prognostics and Health Outcomes, Montreal, Canada

*432
A novel model to estimate a patient’s individual risk of biochemical recurrence after radical prostatectomy
By: Røder M.A.¹, Berg K.D.¹, Thomsen F.B.¹, Kurbegovic S.¹, Rytgaard H.C.², Gruschy L.¹, Brasso K.³, Gerds T.A.², Iversen P.¹
Institutes: Rigshospitalen, University of Copenhagen, Copenhagen Prostate Cancer Center, Department of Urology, Copenhagen, Denmark, ²University of Copenhagen, Dept. of Biostatistics, Copenhagen, Denmark

*433
Long-term oncological outcomes of salvage radical prostatectomy for radio-recurrent/persistent prostate cancer after radiation therapy
By: Vilaseca Cabo A.¹, Nguyen D.¹, Tin A.², Corradi R.¹, Martin-Malburet A.¹, Sandhu J.¹, Leddy L.¹, Sjoberg D.³, Eastham J.³, Scardino P.¹, Touijer K.¹
Institutes: Memorial Sloan-Kettering Cancer Center, Dept. of Urology, New York, United States of America, ²Memorial Sloan-Kettering Cancer Center, Dept. of Epidemiology and Biostatistics, New York, United States of America

*434
Early or delayed radiotherapy in high risk prostate cancer patients treated with radical prostatectomy? Long term results of a multicenter prospective study
By: Maurizi F.¹, Antonogoni P.², Bonetta A.³, Bonetto E.M.⁴, Bortolus R.³, Colombo A.⁶, Frezza G.⁷, Gabriele P.⁹, Giacobazzi P.⁹, Marcenaro M.¹⁰, Mattana F.¹¹, Moro G.¹², Rocchi M.B.L.¹³, Signor M.¹⁴
Efficacy of early and delayed radiation in a prostatectomy cohort adjusted for genomic and clinical risk

By: Ross A.1, Den R.2, Yousefi K.3, Trock B.1, Davicioni E.4, Tosoian J.1, Thompson D.5, Cheoung V.3, Haddad Z.3, Tran P.6, Trabulsi E.7, Gomella L.8, Lallas C.8, Abdollah F.9, Feng F.10, Dicker A.2, Freedland S.11, Karnes J.12, Schaeffer E.1

Institutes: 1Johns Hopkins Hospital, James Buchanan Brady Urological Institute, Baltimore, United States of America, 2Sidney Kimmel Medical College at Thomas Jefferson University, Dept. of Radiation Oncology, Philadelphia, United States of America, 3GenomeDx Biosciences, Dept. of Biostatistics, Vancouver, Canada, 4GenomeDx Biosciences, Dept. of Research and Development, Vancouver, Canada, 5Emmes Canada, Dept. of Biostatistics, Burnaby, Canada, 6Johns Hopkins Hospital, Dept. of Radiation Oncology, Baltimore, United States of America, 7Sidney Kimmel Medical College at Thomas Jefferson University, Dept. of Urology, Episcopal, Oncology, Environmental Health, Philadelphia, United States of America, 8Sidney Kimmel Medical College at Thomas Jefferson University, Dept. of Urology, Philadelphia, United States of America, 9Henry Ford Hospital, Dept. of Vattikutti Urology Institute, Detroit, United States of America, 10University of Michigan, Dept. of Radiation Oncology, Ann Arbor, United States of America, 11Cedars-Sinai Medical Center, Dept. of Surgery, Division of Urology, Los Angeles, United States of America, 12Mayo Clinic, Dept. of Urology, Rochester, United States of America

The time elapsed between radical prostatectomy and postoperative radiotherapy has a significant impact on the subsequent recovery of erectile function

By: Gandaglia G.1, Fossati N.2, Bianchi M.2, Picozzi M.2, Farina E.2, Cucchiara V.2, Larcher A.2, Karakiewicz P.1, Miron M.2, Cozzarini C.2, Montorsi F.2, Briganti A.2

Institutes: 1Ircs Ospedale San Raffaele; Uri, Dept. of Urology, Milan, Italy, 2Ircs Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, 3Magna Graecia University of Catanzaro, Dept. of Urology, Catanzaro, Italy, 4University of Montreal Health Center, Dept. of Urology, Montreal, Canada, 5University Federico II, Dept. of Urology, Naples, Italy, 6Ircs Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy

Detrimental role of pre-prostatectomy neoadjuvant androgen deprivation in node-negative patients treated with adjuvant RT

By: Cozzarini C.1, Noris Chiorda B.1, Deantoni C.1, Briganti A.2, Fiorino C.2, Gandaglia G.2, Fossati N.2, Freschi M.2, Sini C.2, Montironi R.2, Montorsi F.2, Di Muzio N.1

Institutes: 1San Raffaele Scientific Institute, Department of Radiotherapy, Milan, Italy, 2San Raffaele Scientific Institute, Department of Urology, Milan, Italy, 3San Raffaele Scientific Institute, Department of Pathology, Milan, Italy, 4Polytechnic University of The Marche Region, School of Medicine, AOU Ospedali Riuniti, Department of Pathology, Ancona, Italy

PSMA-radioguided surgery for recurrent prostate cancer – mid-term follow-up and novel developments

By: Maurer T.1, Eiber M.3, Wirtz M.2, Robu S.2, Schottelius M.2, Rauscher I.3, Schwaiger M.3, Gschwend J.1, Wester H.-J.2

Institutes: 1Technical University of Munich, Dept. of Urology, Munich, Germany, 2Technical University of Munich, Dept. of Pharmaceutical Radiochemistry, Munich, Germany, 3Technical
When is tumour volume an exclusion criteria for focal therapy? Results from a radical prostatectomy series


Institutes: IRCCS Ospedale San Raffaele, Division of Oncology/Unit of Urology; URI, Milan, Italy

Expression of steroid hormone receptors in residual cancer and stromal cells after neoadjuvant chemohormonal therapy with docetaxal for high-risk localized prostate cancer


Institutes: Akita University School of Medicine, Dept. of Urology, Akita, Japan, Akita University Hospital, Enter For Kidney Disease and Transplantation, Akita, Japan, Akita University Hospital, Dept. of Pathology, Akita, Japan

Neutrophil-to-lymphocyte ratio is associated with survival after radical prostatectomy in prostate cancer


Institutes: Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, National Health Insurance Corporation Ilsan Hospital, Dept. of Urology, Goyang, South Korea, Cheil General Hospital & Women's Healthcare Center, Dept. of Urology, Seoul, South Korea, Inje University College of Medicine, Dept. of Urology, Gimhae, South Korea

Summary and context

A.S. Merseburger, Lübeck (DE)